Jeffrey P Ward
Overview
Explore the profile of Jeffrey P Ward including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
2890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sultan H, Takeuchi Y, Ward J, Sharma N, Liu T, Sukhov V, et al.
Nature
. 2024 Jul;
632(8023):182-191.
PMID: 39048822
CD4 T cells can either enhance or inhibit tumour immunity. Although regulatory T cells have long been known to impede antitumour responses, other CD4 T cells have recently been implicated...
2.
Auberle C, Gao F, Sloan M, Morgensztern D, Winkler L, Ward J, et al.
J Thorac Dis
. 2024 Jul;
16(6):3782-3793.
PMID: 38983151
Background: Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). The purpose...
3.
Meng W, Takeuchi Y, Ward J, Sultan H, Arthur C, Mardis E, et al.
Cancer Immunol Res
. 2024 May;
12(8):988-1006.
PMID: 38768391
Cancer neoantigens have been shown to elicit cancer-specific T-cell responses and have garnered much attention for their roles in both spontaneous and therapeutically induced antitumor responses. Mass spectrometry (MS) profiling...
4.
Singareddy A, Flanagan M, Samson P, Waqar S, Devarakonda S, Ward J, et al.
Clin Lung Cancer
. 2022 Dec;
24(2):114-119.
PMID: 36504141
Introduction: The American Cancer Society has recently reported an increase in the percentage of patients with localized lung cancer from 2004 to 2018, coinciding with the initial lung cancer screening...
5.
Herzog B, Waqar S, Devarakonda S, Ward J, Gao F, Govindan R, et al.
Lung Cancer
. 2022 Sep;
173:101-106.
PMID: 36179540
Objectives: The treatment options for patients with stage IV non-small cell lung cancer (NSCLC) who develop tumor progression after platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) are limited. The combination...
6.
Knapp B, Mezquita L, Devarakonda S, Aldea M, Waqar S, Pepin K, et al.
Front Oncol
. 2022 Apr;
12:856132.
PMID: 35419282
Introduction: Circulating tumor DNA (ctDNA) testing may identify patients at high risk for recurrence following chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC). We evaluated the feasibility of...
7.
Salmon A, Shavkunov A, Miao Q, Jarjour N, Keshari S, Esaulova E, et al.
Cancer Immunol Res
. 2022 Feb;
10(5):597-611.
PMID: 35181783
Immune checkpoint therapy (ICT) using antibody blockade of programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can provoke T cell-dependent antitumor activity that generates durable clinical...
8.
Ward J, Berrien-Elliott M, Gomez F, Luo J, Becker-Hapak M, Cashen A, et al.
Blood
. 2021 Nov;
139(13):1999-2010.
PMID: 34780623
New therapies are needed for patients with relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) who do not benefit from or are ineligible for stem cell transplant and chimeric antigen receptor...
9.
Bagadia P, OConnor K, Wu R, Ferris S, Ward J, Schreiber R, et al.
J Immunol
. 2021 Jun;
207(1):125-132.
PMID: 34135058
The transcriptional repressor has been reported as required for development of a subset of classical dendritic cell (cDCs) called cDC1, which is responsible for cross-presentation. However, mechanisms and in vivo...
10.
Lussier D, Alspach E, Ward J, Miceli A, Runci D, White J, et al.
Proc Natl Acad Sci U S A
. 2021 Jun;
118(24).
PMID: 34099555
Immunotherapies are a promising advance in cancer treatment. However, because only a subset of cancer patients benefits from these treatments it is important to find mechanisms that will broaden the...